Hybridan's Small Cap Wrap

Thursday, Sep 13 2012 by
Hybridans Small Cap Wrap

Animalcare (LON:ANCR) Group (ANCR) [129p/£26.73 million]

One of the leading suppliers of veterinary medicines announced the launch of a new product for problems related to canine ageing. Vitofyllin will be available in tablet form and acts as a central nervous system stimulant for older dogs suffering from dullness, poor demeanour and unwillingness to exercise. This forms part of a collaboration between Animalcare and three of its European partners, and has enhanced the company's in-house expertise having been contract synthesised. The regulatory procedure was also the first time a bioequivalence bio-waiver had been successfully applied for and obtained in Europe. The market in the UK and Ireland is said to be worth £1.5 million per annum.

BlueStar SecuTech (BSST) [6p/£4.4 million]

BlueStar SecuTech, a supplier of digital video surveillance solutions in China, has announced that it has received an order from the Bank of Beijing, worth approximately ¥5 million (£0.5 million). The contract is for the provision of networked surveillance services and solutions for the second part of a project with Bank of Beijing. The company has also won a contract with Shanghai Pudong Development Bank. The order, worth approximately ¥1.7 million (£0.2 million), will help build a network command center in the Chengdu branch.

Craneware (LON:CRW) (CRW) [425p/£114.72 million]

The Edinburgh-headquartered provider of automated revenue integrity solutions for the US healthcare market announced final results for the year to 31 December 2012. Revenue was up 8% to $41.1 million (£25.5 million; 2011: $38.1 million) whilst adjusted pre-tax profit increased by 16% to $10.8 million (2011: $9.3 million). Cash at year end continued at a strong level of $28.8 million (2011: $24.2 million), and a dividend of 5.7p is to be paid taking the total dividend for the period to 10.5p, some 19% higher than the year before (2011: 8.8p).

The company's progress continues to be closely linked with the navigation of the US healthcare market, which is seeing healthcare facilities across the country looking for efficiency gains across their revenue generating areas. Whilst 75-80% of revenues currently come from the Annuity SAAS model, which sees licence fees invoiced over a five-year contract, the balance of revenues continue to come from professional services implementation and a pure SAAS model with monthly invoicing and revenue recognition, as the company seeks to phase these out one can expect to see continuing benefits…

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Services Authority (FSA) rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual partners and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied up on by persons in the UK who are not relevant persons.

Neither this report nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor?s base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or PLUS Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Services Authority and is a member of the London Stock Exchange.


Hybridan LLP
29 Throgmorton Street, London EC2N 2AT

If you would like to receive other research reports from Hybridan, or would like to unsubscribe, please e- mail research@hybridan.com, title e-mail "research reports" or "unsubscribe me" Hybridan LLP is authorised and regulated by the Financial Services Authority Member of the London Stock Exchange


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



Touchstone Innovations plc, formerly Imperial Innovations Group plc, is a technology commercialization company. The Company creates, builds and invests in technology companies and licensing opportunities developed from scientific research focusing on the Golden Triangle. The Company has operations in London, Cambridge and Oxford. The Company supports scientists and entrepreneurs in the commercialization of their ideas and intellectual property by the formation of new companies, providing facilities in the early stages, providing investment and co-investment to manage development, providing operational knowhow and recruiting management teams. It also runs a technology incubator in London. The Company invests in a range of sectors, which include therapeutics, medtech and medical devices, engineering and materials, and information and communications technology. It has access to intellectual property developed at Imperial College London and networks around London, Cambridge and Oxford. more »

LSE Price
315p
Change
 
Mkt Cap (£m)
n/a
P/E (fwd)
n/a
Yield (fwd)
n/a

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD. more »

LSE Price
197.5p
Change
1.3%
Mkt Cap (£m)
161.9
P/E (fwd)
n/a
Yield (fwd)
2.3

DDD Group Plc is a developer and licensor of intellectual property in the advanced imaging market for consumer entertainment products. The Company offers intelligent video software solutions for the video chat/conferencing, gamecasting/Webcasting and social photography markets. Its intelligent video solutions include real time identification of the user from their Webcam image that allows the user's immediate background to be removed and replaced with alternate images, such as live or recorded video game feeds or selfie photographs without the requirement for additional green screen systems or infra-red depth sensors. The software products are designed for the personal computer and mobile device markets. Its products include TriDef SmartCam, TriDef for mobile devices, TriDef 3D for television and TriDef 3D for personal computer (PC). Its TriDef technologies provide solutions for background removal, gaming and three-dimensional (3D) conversion. more »

Price
0.3p
Change
-7.7%
Mkt Cap (£m)
n/a
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is Touchstone Innovations fundamentally strong or weak? Find out More »


What's your view on this article? Log In to Comment Now

You can track all @StockoChat comments via Twitter


About Hybridan

Hybridan

Hybridan is a corporate broker and PLUS markets corporate advisor specialising in fundraising, research and after-market support for small and micro cap companies. We utilise our market knowledge to provide creative financing solutions and strong after-market support. We build long term durable relationships with companies and investors, for the benefit of both. This long term approach, coupled with a high degree of selectivity, yields investments that outperform the market. more »



Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis